Back

Decellularized Normal and Tumor Scaffolds for Cancer Organoid Cultures as a Model of Colorectal Peritoneal Metastases

Varinelli, L.; Guaglio, M.; Brich, S.; Zanutto, S.; Belfiore, A.; Zanardi, F.; Iannelli, F.; Oldani, A.; Costa, E.; Chighizola, M.; Minardi, S. P.; Fortuzzi, S.; Filugelli, M.; Garzone, G.; Vecchi, M.; Pruneri, G.; Kusamura, S.; Baratti, D.; Cattaneo, L.; Parazzoli, D.; Podesta, A.; Milione, M.; Deraco, M.; Pierotti, M. A.; Gariboldi, M.

2021-07-15 cancer biology
10.1101/2021.07.15.452437 bioRxiv
Show abstract

Peritoneal metastases (PM) from colorectal cancer (CRC) are associated with poor survival. The extracellular matrix (ECM) plays a fundamental role in modulating the homing of CRC metastases to the peritoneum. The mechanisms underlying the interactions between metastatic cells and the ECM, however, remain poorly understood and the number of in vitro models available for the study of the peritoneal metastatic process is limited. Here, we show that decellularized ECM of the peritoneal cavity allows the growth of organoids obtained from PM, favoring the development of three-dimensional nodules that maintain the characteristics of in vivo PM. Organoids preferentially grow on scaffolds obtained from neoplastic peritoneum, which are characterized by greater stiffness than normal scaffolds. A gene expression analysis of organoids grown on different substrates reflected faithfully the clinical and biological characteristics of the organoids. An impact of the ECM on the response to standard chemotherapy treatment for PM was also observed. SignificanceEvidence of the value of ex vivo 3D models obtained by combining patient-derived extracellular matrices depleted of cellular components and organoids to mimic the metastatic niche, to be used as a tool to develop new therapeutic strategies in a biologically relevant context, to personalize treatments and increase their efficacy.

Matching journals

The top 17 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3102 papers in training set
Top 16%
6.5%
2
Cancers
200 papers in training set
Top 1%
4.9%
3
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 0.9%
4.9%
4
Biomaterials
78 papers in training set
Top 0.1%
4.0%
5
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
3.6%
6
Frontiers in Oncology
95 papers in training set
Top 1%
3.6%
7
International Journal of Cancer
42 papers in training set
Top 0.3%
3.1%
8
Advanced Science
249 papers in training set
Top 7%
2.8%
9
Cell Death & Disease
126 papers in training set
Top 0.5%
2.8%
10
Journal of Translational Medicine
46 papers in training set
Top 0.5%
2.1%
11
Cancer Research
116 papers in training set
Top 2%
1.9%
12
Cells
232 papers in training set
Top 2%
1.9%
13
iScience
1063 papers in training set
Top 11%
1.9%
14
eLife
5422 papers in training set
Top 39%
1.8%
15
British Journal of Cancer
42 papers in training set
Top 0.8%
1.7%
16
npj Precision Oncology
48 papers in training set
Top 0.5%
1.7%
17
Frontiers in Immunology
586 papers in training set
Top 5%
1.5%
50% of probability mass above
18
PLOS ONE
4510 papers in training set
Top 56%
1.5%
19
Neoplasia
22 papers in training set
Top 0.3%
1.5%
20
Translational Oncology
18 papers in training set
Top 0.2%
1.4%
21
Communications Biology
886 papers in training set
Top 12%
1.4%
22
Cell Communication and Signaling
35 papers in training set
Top 0.6%
1.4%
23
Biomedicines
66 papers in training set
Top 1%
1.4%
24
PLOS Computational Biology
1633 papers in training set
Top 18%
1.4%
25
Computational and Structural Biotechnology Journal
216 papers in training set
Top 6%
1.2%
26
OncoImmunology
22 papers in training set
Top 0.2%
1.2%
27
Journal of Clinical Medicine
91 papers in training set
Top 4%
1.2%
28
Oncogene
76 papers in training set
Top 1%
1.1%
29
BMC Biology
248 papers in training set
Top 3%
0.9%
30
Cell Death Discovery
51 papers in training set
Top 1%
0.9%